The Zhitong Finance App learned that Citibank released a research report saying that last Friday (11th) Tiger Pharmaceuticals (03347) announced the findings of the China Securities Regulatory Commission's investigation of Tiger Pharmaceuticals co-founders Ye Xiaoping and Cao Xiaochun. Among them, the Zhejiang Regulatory Bureau plans to issue separate warnings and fines of 500,000 yuan each against Ye Xiaoping and Cao Xiaochun. The investigation involved two suspected breaches of information disclosure obligations during changes in the company's shareholding. Citi believes that the results are consistent with the bank's previous estimates and eliminate regulatory uncertainty. Citi maintained positive order growth and profit visibility for Tiger Pharmaceuticals, and reaffirmed its “buy” rating and preferred stock status. Tiger Pharmaceuticals (300347.SZ) has a target price of RMB 67 for A-shares and HK$73 for H-shares.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.